NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ALNY

*Your capital is at risk

$219.00

-1.33 (-0.604%)

At Close: Aug 04, 2026

Alnylam Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -61.58. In total, the insiders bought 71.82K and sold 22.73K ALNY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-61.58
● Buy	71.82K shares
● Sell	22.73K shares
28% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -61.58. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Pyott David E I Director	Director	1 441 Value: $430.1K
May 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Schulman Amy W Director	Director	1 802 Value: $537.9K
May 13, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Schulman Amy W Director	Director	11 250 Value: $789.8K
May 13, 2026 Buy	Common Stock M-Exempt	Schulman Amy W Director	Director	11 250 Value: $789.8K
Apr 06, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	199 Value: $66.5K
Apr 06, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	293 Value: $97.2K
Apr 06, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	909 Value: $299.8K
Apr 06, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	56 Value: $17.9K
Apr 06, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	829 Value: $274.0K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	81 Value: $26.2K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	245 Value: $79.1K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	224 Value: $72.0K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	265 Value: $83.9K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	359 Value: $114.0K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	8 Value: $3K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	209 Value: $66.6K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	86 Value: $27.5K
Apr 02, 2026 Sell	Common Stock S-Sale	Mclaughlin Melissa Chief Human Resources Officer	Officer	147 Value: $47.1K
Mar 25, 2026 Buy	Stock Option (Right to Buy)	Mclaughlin Melissa Chief Human Resources Officer	Officer	3 567 Value: $1.16M
Mar 25, 2026 Buy	Common Stock	Mclaughlin Melissa Chief Human Resources Officer	Officer	0 Value: $0
Mar 05, 2026 Sell	Common Stock S-Sale	Garg Pushkal EVP Chief R&d	Officer	654 Value: $210.8K
Mar 05, 2026 Sell	Common Stock S-Sale	Garg Pushkal EVP Chief R&d	Officer	740 Value: $239.4K
Mar 05, 2026 Sell	Common Stock S-Sale	Garg Pushkal EVP Chief R&d	Officer	500 Value: $163.0K
Mar 05, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	124 Value: $39.9K
Mar 05, 2026 Sell	Common Stock S-Sale	Fitzgerald Kevin Joseph Cso & EVP, Head Of Research	Officer	233 Value: $75.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALNYLAM PHARMACEUTICALS

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...

Read Full Profile Here